Introduction

In 2026 a new wave of functional beverages is crossing a crucial threshold: what began in direct‑to‑consumer (DTC) routes and specialist shelves is now appearing in mainstream supermarkets and high‑street cafés. These are not simply CBD drinks — they are CBD‑adjacent, adaptogen and nootropic formulations designed for on‑the‑go focus, mood and social wellness. Retail moves by brands such as Neutonic, Trip and Happy Panda are reshaping where shoppers meet these products and who buys them.

What's trending

The headline trend is mainstream distribution. Neutonic closed a $6M raise in 2026 to scale retail expansion and is launching into 500 Sainsbury’s stores as part of a major rollout into mainstream channels. Trip has already taken a similar path, successfully shifting shelf space out of specialty shops into mainstream supermarkets and high‑street coffee chains, achieving roughly 33% market awareness in beverage categories tracked by industry monitoring. Meanwhile, Happy Panda’s March 2026 launch of a Cognizin (citicoline) nootropic RTD sold out half its initial stock within a month, highlighting vigorous early demand for clinically positioned nootropic drinks.

Category growth and retailer response

Market research points to rapid expansion: estimates for the nootropic and functional beverage category cluster around a 13–17% compound annual growth rate (CAGR) into the early 2030s. Supermarkets and mainstream retailers (Sainsbury’s, Tesco and others) are allocating more shelf space to brain‑health, adaptogen and CBD‑adjacent beverages, while convenience and fitness channels accelerate penetration for shot and RTD formats. In short, functional drinks are moving from niche counters to mass retail aisles.

Why it matters

The retail shift signals more than wider distribution — it reframes consumption occasions and consumer expectations. Several forces are at play:

• Consumer demand for day‑time wellness: Younger shoppers and the growing ‘sober‑curious’ demographic favour low‑alcohol or non‑alcoholic alternatives that provide mood and cognitive support in social and work environments.
• Channel realignment: Supermarkets and convenience channels want fast‑moving, premium‑margin SKUs that attract under‑35s; functional drinks fit perfectly into chilled‑drink and grab‑and‑go strategies.
• Product innovation: Formulations combining adaptogens and nootropics (lion’s mane, rhodiola, Cognizin, L‑theanine, B‑vitamins) with CBD‑adjacent ingredients allow brands to market multi‑functional benefits — stress modulation, focus, and social‑wellness — without medical claims.

For retailers, these products increase basket appeal and the length of stay in chilled aisles; for brands, mainstream listings unlock scale and discoverability beyond high‑touch DTC channels.

Examples in action

Three recent launches show how the playbook has evolved.

Neutonic — scaling to supermarkets

Neutonic’s $6M funding round in 2026 is explicitly aimed at accelerating retail expansion. The brand’s entry into 500 Sainsbury’s stores is a landmark: it demonstrates retailer confidence in CBD‑adjacent adaptogen positioning and the appetite for move‑fast rollouts. For shoppers, this means encountering functional cans and RTDs alongside mainstream wellness beverages rather than confined to niche health shelves.

Trip — from niche to high street

Trip’s strategy centred on distribution partnerships and in‑store sampling, shifting awareness from 0% in many mainstream channels to roughly 33% in tracked beverage categories. That awareness conversion is what turns curious browsers into habitual buyers — and gives supermarkets the data to expand listings.

Happy Panda — demand for clinically positioned nootropics

Happy Panda’s March 2026 Cognizin nootropic RTD sold half its initial stock in a month, underscoring consumer interest in nootropics framed with clinical ingredients. Cognizin (citicoline) and similar actives are enabling brands to pitch cognitive lift and mental clarity in ways that appeal to performance‑oriented and sober‑curious shoppers alike.

Who is buying?

Research and sales patterns point to a core audience: under‑35s, urban professionals and the sober‑curious. Mintel and other industry forecasters show mood and mental‑wellness drinks resonate strongly with younger buyers who prioritise functional, low‑alcohol lifestyle choices. Fitness and performance channels are also important: gym cafés, boutique studios and healthfood retailers provide access to consumers seeking pre‑workout focus or recovery support.

Product innovation and formats

The category is diversifying across formats — RTD cans, concentrated shots, instant sticks and even flavour‑forward sodas — and leaning into multi‑functional formulations. Expect to see CBD‑adjacent pairings with adaptogens and nootropics (lion’s mane, rhodiola, Cognizin, L‑theanine, B‑vitamins) designed to offer combined stress, focus and social‑wellness benefits. This breadth of format makes it easier for retailers to fit products into different mission‑based bays: energy, relaxation, recovery and cognitive support.

Practical note for shoppers

As these drinks land in supermarkets, shoppers will benefit from greater choice and the ability to compare ingredient lists side by side. For those who prefer preparing functional beverages at home, complementary options also exist — for example, premium CBD coffee fans may enjoy Cannacoffee Original CBD Coffee Pods or Cannacoffee Original CBD Whole Bean, or enhance a favourite drink with a CBD Drinks Enhancer. These at‑home options mirror the convenience and ritual many shoppers seek in RTD formats.

Future outlook

Expect continued momentum: retailers will expand shelf space where gross margins and turnover justify listings, and brands will pursue hybrid commercial strategies, combining DTC subscription economics with large‑scale retail presence. The category’s projected 13–17% CAGR into the early 2030s suggests plenty of runway for innovation, but differentiation will come from credible ingredient stories, transparent sourcing and clear on‑pack guidance that complies with UK advertising and regulatory expectations.

Brands that balance clinical positioning (citicoline, nootropics) with accessible formats (shots, cans, sticks) will likely lead mainstream adoption. Meanwhile, the shopper profile will broaden as older segments experiment with mood and cognitive drinks, though the under‑35 cohort and sober‑curious social buyers will remain the core growth engine.

Conclusion

2026 marks a turning point: CBD‑adjacent adaptogen and nootropic drinks are no longer an online or specialist curiosity — they are becoming part of everyday retail. With major rollouts such as Neutonic’s Sainsbury’s expansion, Trip’s mainstream awareness gains and Happy Panda’s rapid sell‑through, the functional beverage aisle is evolving to meet demand for on‑the‑go mood and cognitive support. For shoppers and retailers alike, this is an opportunity to explore new rituals and formats — on the shelf and at home — as the category matures into mainstream British retail.